Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
i-Nelita is a specialized renal nutrition supplement developed and marketed by Steadfast Medishield (now Steadfast Limited) for the dietary management of patients with chronic kidney disease (CKD). Formulated as an oral sachet, it typically contains a comprehensive blend of high-quality whey protein, essential amino acids, vitamins, and minerals. The product is specifically designed to provide nutritional support for patients, particularly those undergoing dialysis who are at high risk of protein-energy wasting (PEW). By supplying essential building blocks for protein synthesis in a kidney-friendly formulation, i-Nelita helps maintain nutritional status and a positive nitrogen balance while minimizing the accumulation of metabolic waste products that the kidneys can no longer effectively filter. It is used as part of a broader renal care regimen to improve the overall health and quality of life of patients with impaired renal function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on i-Nelita.